Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedApr 16, 2026
DataAggregated Company Financials
Companies20
  • 7D4.4%
  • 3M-27.6%
  • 1Y-33.4%
  • YTD-21.1%

Over the last 7 days, the Healthcare industry has risen 4.6%, driven by gains from Novo Nordisk of 5.2%. In contrast, the industry has lost 35% in the last 12 months. Looking forward, earnings are forecast to grow by 4.8% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 16 Apr 2026DKK 1.5tDKK 447.1bDKK 129.9b19x11.9x3.4x
Sat, 14 Mar 2026DKK 1.5tDKK 448.1bDKK 130.1b16.8x11.6x3.4x
Mon, 09 Feb 2026DKK 1.8tDKK 448.2bDKK 134.9b16.7x13.1x3.9x
Wed, 07 Jan 2026DKK 2.1tDKK 453.9bDKK 136.9b17.9x15.5x4.7x
Fri, 05 Dec 2025DKK 1.9tDKK 454.0bDKK 136.9b17x13.6x4.1x
Sun, 02 Nov 2025DKK 1.9tDKK 448.0bDKK 141.9b17.2x13.4x4.3x
Tue, 30 Sep 2025DKK 2.0tDKK 447.4bDKK 141.7b18x14.4x4.6x
Thu, 28 Aug 2025DKK 2.1tDKK 447.6bDKK 141.8b24.3x14.5x4.6x
Sat, 26 Jul 2025DKK 2.5tDKK 423.1bDKK 124.5b30.1x19.9x5.9x
Mon, 23 Jun 2025DKK 2.6tDKK 423.5bDKK 124.6b30.4x20.6x6.1x
Wed, 21 May 2025DKK 2.5tDKK 424.3bDKK 125.1b24.1x19.9x5.9x
Fri, 18 Apr 2025DKK 2.3tDKK 409.2bDKK 121.3b21.8x19.1x5.7x
Sun, 16 Mar 2025DKK 2.8tDKK 409.5bDKK 121.3b24.9x23.5x7x
Tue, 11 Feb 2025DKK 3.3tDKK 408.3bDKK 118.3b28.4x27.6x8x
Thu, 09 Jan 2025DKK 3.3tDKK 387.5bDKK 111.3b29.9x29.6x8.5x
Sat, 07 Dec 2024DKK 4.0tDKK 387.3bDKK 111.3b31.3x36.3x10.4x
Mon, 04 Nov 2024DKK 4.0tDKK 372.2bDKK 107.2b34.5x37.1x10.7x
Wed, 02 Oct 2024DKK 4.1tDKK 372.0bDKK 107.1b36.3x38.4x11.1x
Fri, 30 Aug 2024DKK 4.7tDKK 371.8bDKK 107.1b33.8x44.1x12.7x
Sun, 28 Jul 2024DKK 4.5tDKK 355.4bDKK 106.3b35.9x42.1x12.6x
Tue, 25 Jun 2024DKK 5.0tDKK 355.3bDKK 106.2b34.8x46.7x14x
Thu, 23 May 2024DKK 4.7tDKK 355.3bDKK 106.2b37.9x44.1x13.2x
Sat, 20 Apr 2024DKK 4.4tDKK 341.3bDKK 99.6b32.8x44.3x12.9x
Mon, 18 Mar 2024DKK 4.6tDKK 341.2bDKK 99.6b39.3x46.5x13.6x
Wed, 14 Feb 2024DKK 4.3tDKK 340.5bDKK 98.6b34.4x43.3x12.5x
Fri, 12 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b33.8x42.1x11.8x
Sun, 10 Dec 2023DKK 3.5tDKK 320.6bDKK 90.0b33.8x38.9x10.9x
Tue, 07 Nov 2023DKK 3.6tDKK 318.7bDKK 90.3b29.2x40x11.3x
Thu, 05 Oct 2023DKK 3.4tDKK 305.5bDKK 82.2b32.5x40.9x11x
Sat, 02 Sep 2023DKK 3.5tDKK 305.4bDKK 82.2b36.7x42x11.3x
Mon, 31 Jul 2023DKK 2.9tDKK 287.2bDKK 75.5b37.2x38.5x10.1x
Wed, 28 Jun 2023DKK 3.0tDKK 287.0bDKK 75.5b38.6x39.2x10.3x
Fri, 26 May 2023DKK 3.1tDKK 287.1bDKK 75.5b41.2x40.9x10.8x
Sun, 23 Apr 2023DKK 3.2tDKK 272.6bDKK 68.5b44x46.7x11.7x
Price to Earnings Ratio

46.7x


Total Market Cap: DKK 3.2tTotal Earnings: DKK 68.5bTotal Revenue: DKK 272.6bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 31.4x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 11.6x which is lower than its 3-year average PE of 31.4x.
  • The 3-year average PS ratio of 9.0x is higher than the industry's current PS ratio of 3.4x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 24% per year over the last three years.
  • Revenues for these companies have grown 18% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market2.69%
Healthcare4.36%
Healthcare Services11.00%
Pharma4.83%
Medical Equipment2.99%
Biotech2.44%
Life Sciences2.35%
Healthtech-5.27%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 548x.
    • Analysts are expecting annual earnings growth of 87.6%, which is higher than its past year's earnings decline of 99.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 88% over the next 5 years.
  • This is better than its past earnings decline of 100% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 7.0% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVO B Novo NordiskDKK 251.854.9%
+DKK 51.9b		-40.2%PE10.9x
DEMANT DemantDKK 213.4011.3%
+DKK 4.6b		-4.6%PE19x
GMAB GenmabDKK 1.84k2.8%
+DKK 3.1b		42.4%PE18.5x
HLUN B H. LundbeckDKK 41.584.6%
+DKK 1.8b		45.6%PE12.9x
ALK B ALK-AbellóDKK 213.803.5%
+DKK 1.6b		43.9%PE39.6x

Latest News

GMAB
DKK 1,839.00
Genmab
7D
2.8%
1Y
42.4%
GUBRA
DKK 344.60
Gubra
7D
-2.9%
1Y
-3.2%

GUBRA: Obesity Study And Ventures Unit Will Drive Long Term Upside

Analysts have kept their DKK 469.5 price target on Gubra unchanged, citing only marginal adjustments to assumptions such as the discount rate and forward P/E as the basis for this maintained view. What's in the News Gubra submitted a clinical trial application in Germany for GUB-UCN2, a first in human Phase 1/2a study designed to assess safety, tolerability, pharmacokinetics and preliminary efficacy, including muscle volume and muscle function endpoints, in about 188 participants across multiple indications and patient groups (Key Developments).
NOVO B
DKK 251.85
Novo Nordisk
7D
4.9%
1Y
-40.2%

Novo Nordisk A/S (NOVO B): The "Volume Pivot" and the 2026 Shift to Affordable Access

Novo Nordisk A/S (NOVO B) closed the April 10, 2026, session at 240.65 DKK on the Nasdaq Copenhagen, marking a modest recovery from its March lows. The central narrative for 2026 is "The Great Pricing Pivot" : After years of triple-digit growth driven by Wegovy and Ozempic, Novo Nordisk has entered a "Volume-over-Price" era.
BIOPOR
DKK 0.93
BioPorto
7D
-9.5%
1Y
-37.0%
COLO B
DKK 433.70
Coloplast
7D
-0.3%
1Y
-38.3%

COLO B: New CEO Appointment Will Support Future Re Rating Potential

The updated analyst price target for Coloplast has been reduced by DKK 6.53. This change reflects a slight reset in fair value as analysts incorporate higher discount rates, marginally softer margin assumptions, and recent price target cuts, along with mixed rating changes across the Street.
ALK B
DKK 213.80
ALK-Abelló
7D
3.5%
1Y
43.9%

ALK B: Future Upside Will Come From Wider Needle Free Anaphylaxis Treatment Adoption

Analysts have adjusted their DKK price targets for ALK-Abelló to reflect updated assumptions for revenue growth of 13.31%, profit margin of 20.66% and a future P/E of 34.79. This suggests a modest recalibration in how the company’s earnings power is being valued.
STENO
DKK 0.96
Stenocare
7D
-6.9%
1Y
192.1%
DEMANT
DKK 213.40
Demant
7D
11.3%
1Y
-4.6%

DEMANT: Recent Upgrades And 2026 Guidance May Support Re Rating

The updated analyst price target for Demant now sits at DKK 232, up modestly from DKK 232. The small adjustment reflects a mix of recent upgrades and price target cuts as analysts reassess assumptions for discount rates, revenue growth, profit margins and future P/E levels.
ZEAL
DKK 299.90
Zealand Pharma
7D
1.5%
1Y
-29.4%

ZEAL: Obesity Partnership With Roche And AI Hub Will Drive Future Re Rating

Analysts have sharply reduced price targets on Zealand Pharma, with several firms shifting to more neutral ratings and resetting expectations to a range of around DKK 275 to DKK 460. This reflects more conservative views on petrelintide's role in a competitive obesity market.
AMBU B
DKK 67.80
Ambu
7D
3.2%
1Y
-40.7%

AMBU B: Refined Discount Rate And P/E Expectations Will Support Future Upside

Analysts have lowered their price target on Ambu by DKK 12. This reflects small adjustments to fair value, discount rate, revenue growth, profit margin and future P/E assumptions following recent research updates.
HLUN B
DKK 41.58
H. Lundbeck
7D
4.6%
1Y
45.6%

HLUN B: Late-Stage Neurology Trials And Dividend Policy Will Support Margins

Analysts have adjusted their DKK price target on H. Lundbeck slightly, reflecting only minor tweaks to revenue growth, profit margin, and future P/E assumptions in their updated models.
VIRO
DKK 11.10
ViroGates
7D
-0.9%
1Y
73.4%
CHEMM
DKK 330.60
ChemoMetec
7D
8.1%
1Y
-31.0%
PEG
DKK 0.08
Pharma Equity Group
7D
-6.1%
1Y
-5.5%
NNIT
DKK 44.15
NNIT
7D
-5.5%
1Y
-35.0%